XNASBFRIW
Market cap8mUSD
Jan 14, Last price
0.08USD
1D
-8.24%
1Q
145.28%
IPO
-93.95%
Name
Biofrontera Inc
Chart & Performance
P/E
—
P/S
0.02
EPS
—
Div Yield, %
%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
34m
+18.82%
Net income
-20m
L+3,045.47%
CFO
-25m
L+53.68%
Earnings
Mar 13, 2025
Profile
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 34,071 18.82% | 28,674 18.98% | |||
Cost of revenue | 56,648 | 51,155 | |||
Unusual Expense (Income) | |||||
NOPBT | (22,577) | (22,481) | |||
NOPBT Margin | |||||
Operating Taxes | 14 | 32 | |||
Tax Rate | |||||
NOPAT | (22,591) | (22,513) | |||
Net income | (20,131) 3,045.47% | (640) -98.30% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 4,507 | 14,021 | |||
BB yield | -105.22% | -72.36% | |||
| Debt | |||||
Debt current | 5,286 | 498 | |||
Long-term debt | 2,299 | 2,194 | |||
Deferred revenue | 2,400 | ||||
Other long-term liabilities | 4,247 | 2,863 | |||
Net debt | 6,164 | (27,877) | |||
| Cash flow | |||||
Cash from operating activities | (24,895) | (16,199) | |||
CAPEX | (5) | (38) | |||
Cash from investing activities | 619 | (5,156) | |||
Cash from financing activities | 8,411 | 14,021 | |||
FCF | (31,583) | (9,091) | |||
| Balance | |||||
Cash | 1,421 | 27,756 | |||
Long term investments | 2,813 | ||||
Excess cash | 29,135 | ||||
Stockholders' equity | (99,648) | (79,491) | |||
Invested Capital | 114,751 | 109,979 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 1,546 | 1,057 | |||
Price | 2.77 -84.89% | 18.33 -87.81% | |||
Market cap | 4,283 -77.89% | 19,377 -84.94% | |||
EV | 10,447 | (8,500) | |||
EBITDA | (21,513) | (21,309) | |||
EV/EBITDA | 0.40 | ||||
Interest | 600 | 195 | |||
Interest/NOPBT | |||||